Sign inJoin waitlistJoin the waitlist

Alissa Marr

Program Director, UNMC Oncology & Hematology Fellowship · University of Nebraska Medical Center College of Medicine

Credentials: · · · · ·

History

UNMC Oncology & Hematology Fellowship · University of Nebraska Medical Center College of Medicine
Present
University of Nebraska Medical Center College of Medicine
Present
University of Nebraska Medical Center College of Medicine
Present

Hematology and Medical Oncology
University of Nebraska Medical Center College of Medicine
2007–2010
Internal Medicine
University of Nebraska Medical Center College of Medicine
2003–2006
University of Nebraska Medical Center
1999–2003

Research

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Review · Journal of the National Comprehensive Cancer Network · 2022 · 415 citations
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024 · 118 citations
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2020 · 64 citations

Apar Ganti
17 papers
Ramya Thota
7 papers
Richard Schilsky
7 papers
Chi Zhang
4 papers · 1 as a resident
PG
Philip Gold
4 papers
TC
Timothy Cannon
4 papers
DB
Deepti Behl
3 papers
EP
Evan Pisick
3 papers
Funda Meric-Bernstam
3 papers
Herbert Duvivier
3 papers
Olatunji Alese
3 papers
Vinicius Ernani
3 papers

Clinical trials

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2020–2026
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Site PI · Recruiting · Phase 2
American Society of Clinical Oncology
2016–2028